102 related articles for article (PubMed ID: 8847155)
1. Influence of aging on the oxidative and conjugative metabolism of propranolol.
Tateishi T; Fujimura A; Shiga T; Ohashi K; Ebihara A
Int J Clin Pharmacol Res; 1995; 15(3):95-101. PubMed ID: 8847155
[TBL] [Abstract][Full Text] [Related]
2. The influence of diltiazem versus cimetidine on propranolol metabolism.
Tateishi T; Ohashi K; Fujimura A; Ebihara A
J Clin Pharmacol; 1992 Dec; 32(12):1099-104. PubMed ID: 1487547
[TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.
Sowinski KM; Burlew BS
Pharmacotherapy; 1997; 17(6):1305-10. PubMed ID: 9399616
[TBL] [Abstract][Full Text] [Related]
4. Quantitative account of propranolol metabolism in urine of normal man.
Walle T; Walle UK; Olanoff LS
Drug Metab Dispos; 1985; 13(2):204-9. PubMed ID: 2859169
[TBL] [Abstract][Full Text] [Related]
5. Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing.
Lankford SM; Maskasame C; Bai SA
Drug Metab Dispos; 1994; 22(5):776-87. PubMed ID: 7835231
[TBL] [Abstract][Full Text] [Related]
6. Selective induction of propranolol metabolism by smoking: additional effects on renal clearance of metabolites.
Walle T; Walle UK; Cowart TD; Conradi EC; Gaffney TE
J Pharmacol Exp Ther; 1987 Jun; 241(3):928-33. PubMed ID: 3598909
[TBL] [Abstract][Full Text] [Related]
7. Stereochemical composition of propranolol metabolites in the dog using stable isotope-labeled pseudoracemates.
Walle T; Wilson MJ; Walle UK; Bai SA
Drug Metab Dispos; 1983; 11(6):544-9. PubMed ID: 6140137
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic interaction study of avitriptan and propranolol.
Marathe PH; Greene DS; Kollia GD; Barbhaiya RH
Clin Pharmacol Ther; 1998 Mar; 63(3):367-78. PubMed ID: 9542480
[TBL] [Abstract][Full Text] [Related]
9. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
[TBL] [Abstract][Full Text] [Related]
10. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
Ring JA; Ghabrial H; Ching MS; Shulkes A; Smallwood RA; Morgan DJ
Drug Metab Dispos; 1995 Feb; 23(2):190-6. PubMed ID: 7736910
[TBL] [Abstract][Full Text] [Related]
11. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
12. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
13. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
[TBL] [Abstract][Full Text] [Related]
14. Propranolol concentrations after oral administration in term and preterm neonates.
Filippi L; Cavallaro G; Fiorini P; Malvagia S; Della Bona ML; Giocaliere E; Bagnoli P; Dal Monte M; Mosca F; Donzelli G; la Marca G
J Matern Fetal Neonatal Med; 2013 May; 26(8):833-40. PubMed ID: 23205867
[TBL] [Abstract][Full Text] [Related]
15. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic comparison of propranolol and atenolol in people with primary hypertension].
Telatyńska-Smieszek B
Ann Acad Med Stetin; 2002; 48():367-80. PubMed ID: 14601489
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects.
Wójcicki J; Jaroszynska M; Droździk M; Pawlik A; Gawrońska-Szklarz B; Sterna R
Biopharm Drug Dispos; 2003 Jul; 24(5):211-8. PubMed ID: 12784321
[TBL] [Abstract][Full Text] [Related]
18. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans.
Kiriyama A; Honbo A; Iga K
Int J Pharm; 2008 Feb; 349(1-2):53-60. PubMed ID: 17765415
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states.
Jacobs G; Whittem T; Sams R; Calvert C; Ferguson D
Am J Vet Res; 1997 Apr; 58(4):398-403. PubMed ID: 9099387
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of propranolol and its metabolites in horses after intravenous or oral administration.
Aramaki S; Mori M; Nakata M; Shinohara A; Koizumi T
Biol Pharm Bull; 2000 Nov; 23(11):1333-40. PubMed ID: 11085362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
